INmune Bio Inc
inmunebio.comWhat Do They Do?
Develops drug candidates that target the innate immune system for patients with a rare skin disease, Alzheimer’s disease, and prostate cancer.
10-K for FY2025, filed Mar 30, 2026INmune Bio is a clinical-stage biotechnology company dedicated to developing and commercializing a pipeline of product candidates designed…View ↗
Lead Program: CORDStrom™ for RDEB Our primary focus is the treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB) using CORDStrom…View ↗
XPro1595 (XPro): A next-generation protein therapeutic that targets neuroinflammation by selectively neutralizing soluble TNF. XPro has…View ↗
INKmune™: A novel natural killer (NK) cell-priming platform designed to harness the patient’s own innate immune system to eliminate cancer…View ↗
How Do They Make Money?
$50K
-
10-K for FY2025, filed Mar 30, 2026
$50K ↗
Who Are Their Customers?
INmune Bio supplied CORDStrom to Great Ormond Street Children’s Hospital and Birmingham Children’s Hospital for the MissionEB study; it was compensated for product used in the trial.
10-K for FY2025, filed Mar 30, 2026From 2020 until mid-2024, the Company supplied CORDStrom as an investigational medical product to the Great Ormond Street Children’s…View ↗
Do Revenues Turn Into Profits?
No. It lost $45.9M in FY2025.
10-K for FY2025, filed Mar 30, 2026
−$47.4MView ↗
10-K for FY2025, filed Mar 30, 2026
−$45.9MView ↗
10-K for FY2025, filed Mar 30, 2026
−$23.6MView ↗
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 6, 2026
−$1.3MView ↗
- ▼ −95% (Loss)
- vs −$24.5M in Q2 FY2025
-
May 5, 2026
Expanded Anthony Nolan collaboration supports CORDStrom’s broader disease pipeline
The agreement secures long-term umbilical cord tissue and names oncology and inflammatory diseases among CORDStrom’s intended areas.
Sources
8-K, filed May 5, 2026
The expanded collaboration with AN pursuant to the Amended and Restated Agreement secures the long-term provision of high-quality umbilical…View ↗
Shrinking. Revenue fell 72% in 4 years, from $181K in FY2021 to $50K in FY2025, about 28% a year.
From research supply to lead therapy
The earlier report described CORDStrom as a supply opportunity for research groups and drug companies. The latest report positions it as the lead program for RDEB, alongside other clinical programs.
10-K for FY2022, filed Mar 2, 2023 10-K for FY2025, filed Mar 30, 2026We continue to look for ways to utilize our unique capabilities to optimize clinical application of cell therapies. We believe that we have…View ↗
Lead Program: CORDStrom™ for RDEB Our primary focus is the treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB) using CORDStrom…View ↗
CORDStrom has recently completed a pivotal, blinded, randomized cross-over trial. Based on these data, the Company is transitioning toward…View ↗
Neuroinflammation and Oncology Pipelines In addition to our lead rare disease program, the Company is advancing two other clinical-stage…View ↗
XPro1595 (XPro): A next-generation protein therapeutic that targets neuroinflammation by selectively neutralizing soluble TNF. XPro has…View ↗
INKmune™: A novel natural killer (NK) cell-priming platform designed to harness the patient’s own innate immune system to eliminate cancer…View ↗
Loading...
